RECT vs TBHC

RECT exhibits strong fundamental health with a Piotroski F-Score of 7/9 and a conservative Debt/Equity ratio of 0.35. The stock is significantly undervalued, trading at $1.62 against a Graham Number of $2.57 and an intrinsic value of $5.90. Despite a devastating one-year price decline of 59.4%, explosive earnings growth (125% YoY) and a recent short-term price recovery suggest a potential value reversal. The company significantly outperforms sector averages in profitability and leverage, though it remains a high-risk micro-cap.

TBHC exhibits severe financial distress, anchored by a critical Piotroski F-Score of 1/9 and a negative Price-to-Book ratio of -0.48, indicating negative shareholder equity. The company is facing a liquidity crisis, evidenced by a Quick Ratio of 0.06, suggesting it cannot meet short-term obligations without selling inventory. With declining revenue (-9.60% YoY) and a 5-year price collapse of 96.7%, the business model appears unsustainable in its current form. The lack of a valid Altman Z-Score combined with these metrics points toward a high risk of insolvency.